Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well niraparib and dostarlimab work in treating patients with
germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other
places in the body (metastatic). Niraparib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
dostarlimab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may kill more
tumor cells.